Biblio
2023
Gordon LI, Liu FFei, Braverman J, Hoda D, Ghosh N, Hamadani M, Hildebrandt GC, Peng L, Guo S, Shi L, et al. Lisocabtagene maraleucel for second-line relapsed or refractory large B-cell lymphoma: patient-reported outcomes from the PILOT study. Haematologica. 2023.
Lontos K, Tsagianni A, Agha M, Raptis A, Hou J-Z, Farah R, Redner RL, Im A, Dorritie KA, Sehgal A, et al. Prognostic significance of blast immunophenotype on first post-induction bone marrow biopsy. Leuk Lymphoma. 2023:1-3.
2022
Sehgal A, Hoda D, Riedell PA, Ghosh N, Hamadani M, Hildebrandt GC, Godwin JE, Reagan PM, Wagner-Johnston N, Essell J, et al. Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study. Lancet Oncol. 2022.
2016
Hartsock B, Lim MJ, Roth CGarcia, Raptis N, Weber D, Sehgal A, Boyiadzis M, Raptis A, Hou J-Z, Im A, et al. ICU intervention during induction chemotherapy for adult patients with newly diagnosed acute myeloid leukemia. Leuk Res. 2016;48:16-19.
]